New prolonged-release metformin improves gastrointestinal tolerability

British Journal of Diabetes and Vascular Disease

Volumn 4, Issue 4, 2004, Pages 273-277

  Davidson, Jaime ^a   Howlett, Harry ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b MERCK KGAA   (Germany)

Author keywords

Adherence; Gastrointestinal tolerability; Metformin; Oral antidiabetic therapy; Prolonged release formulation; Type 2 diabetes

Indexed keywords

CHOLESTEROL; GLUCOPHAGE SR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO;

ABDOMINAL PAIN; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG TOLERABILITY; DYSPEPSIA; FLATULENCE; GASTROINTESTINAL TOXICITY; HUMAN; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; REVIEW; SUSTAINED RELEASE FORMULATION; TABLET FORMULATION;

EID: 4444273085     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514040040041101     Document Type: Review

References (16)

1. Howlett HC, Bailey CJ. A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf 1999;20:489-503.
2. Campbell IW, Howlett HC. Worldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis. Diabetes Metab Rev 1995;11(suppl 1):S57-S62.
3. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
4. National Institute for Clinical Excellence. Management of type 2 diabetes - Management of blood glucose - NICE summary. Available at National Library for Health website, http://www.nelh.nhs.uk/guidelinesdb/html/fulltext-guidelines/ Bloodglucose.html, last accessed by author January 29 2004.
5. Davidson JA. The treatment of type II diabetes in Texas: current issues for managed care and employers. Diabetes Care 1997;20:44-51.
6. Davidson J. Revised standards for the treatment of type 2 diabetes in Texas. Diabetes Care 1999;22:1219-20.
7. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997;103:491-7.
8. Scarpello JHB. Optimal dosing strategies for maximising the clinical response to metformin in type 2 diabetes. Br J Vasc Dis 2001;1:28-36.
9. Paes AHP, Bakker A, Soe-Agnie S-J. Impact of dosage frequency on patient compliance. Diabetes Care 1997;20:1512-17.
10. Fujioka K, Bruce S, Joyal S, Swanink R, Pans M. Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage® XR) in type 2 diabetic patients with inadequate glycemic control despite prior treatment with diet and exercise: results from two double-blind, placebo-controlled studies. Diabetes Obes Metab 2004 (in press).
11. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin dependent diabetes mellitus. N Engl J Med 1995;333:541-9.
12. Fujioka K, Joyal S, Bruce S. Type 2 diabetes patients switched from immediate-release metformin bid to an extended-release qd formulation in a randomized, controlled trial maintain comparable glycemic control. Clin Ther 2003;25:515-29.
13. Blonde L, Dailey GE, Jabbour SA, Reasner CA, Mills DJ. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets - results of a retrospective cohort study. Curr Med Res Opin 2004;20:565-72.
14. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
15. Timmins F, Donahue S, Meeker J, Marathe P. Steady-state pharmacokinetics of a novel extended-release metformin formulation. Clin Pharmacokinet 2004 (in press).
16. Marathe P, Turner K. Steady-state pharmacokinetics of the metformin extended-release tablet versus immediate-release metformin in healthy subjects. Diabetes 2002;51(suppl 2):A474.